Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
NOVA Stock Chart & Stats
€40.85
€2.60(3.26%)
At close: 4:00 PM EST
€40.85
€2.60(3.26%)
Day’s Range― - ―
52-Week Range€36.10 - €90.40
Previous CloseN/A
Volume1.40K
Average Volume (3M)6.08K
Market Cap
€187.34B
Enterprise Value€1.47T
Total Cash (Recent Filing)€26.96B
Total Debt (Recent Filing)€130.96B
Price to Earnings (P/E)13.4
Beta0.95
Next Earnings
May 06, 2026EPS Estimate
0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding3,390,128,000
10 Day Avg. Volume6,417
30 Day Avg. Volume6,079
Financial Highlights & Ratios
PEG Ratio8.17
Price to Book (P/B)7.42
Price to Sales (P/S)4.84
P/FCF Ratio25.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€47.05Price Target Upside15.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial UptakeStronger early prescription uptake of the oral weight‑loss pill suggests a lower‑priced oral formulation can rebuild patient volumes and offset some pricing pressure.
Marketing And PromotionA large promotional and direct‑to‑consumer advertising push behind the oral Wegovy product could boost patient awareness and accelerate adoption, supporting sales recovery.
Pipeline DiversificationLate‑stage trial readouts and potential approvals for treatments beyond obesity, including diabetes candidates, offer high‑reward upside that could materially improve growth if successful.
Bears Say
Competitive PressureRival therapies and a low‑cost compounded oral alternative are likely to capture price‑sensitive patients, eroding market share for both injectable and branded oral products.
Guidance And Access UncertaintyManagement's cautious guidance and unclear insurance coverage dynamics signal that volume recovery may be gradual, keeping near‑term growth under pressure.
Pricing And ReimbursementPricing concessions, channel‑mix shifts, and government pricing rules are expected to reduce revenue per treatment and create headwinds for overall sales.
Novo Nordisk News
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €36.10 and its highest was €90.40 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is €187.34B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 06, 2026 which is in 82 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Feb 04, 2026. The company reported €0.804 earnings per share for the quarter, beating the consensus estimate of €0.778 by €0.026.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.69.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.804 in its last earnings report, beating expectations of €0.778. Following the earnings report the stock price went down -6.11%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€47.05 (15.19% Upside)
€47.05 (15.19% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 85%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 79%
Bearish news 37%
Bearish news 37%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.73%
12-Months-Change
Fundamentals
Return on Equity
61.25%
Trailing 12-Months
Asset Growth
31.99%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NOVA Company Deck
NOVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum in obesity and GLP-1 franchises (notably the successful Wegovy pill launch, robust GLP-1 volume share, and meaningful R&D readouts such as CagriSema and zenagamtide) alongside solid cash generation and shareholder returns. Offsetting these positives are substantial near-term headwinds driven by pricing pressure, policy impacts (MFN/MFP), loss of exclusivity risk, margin compression and a conservative 2026 outlook (adjusted sales and operating profit guidance of -5% to -13% CER). Management is bullish on long-term market expansion and pipeline potential but explicit near-term guidance and exceptional costs temper the tone. Overall, positives (product launches, R&D wins, market leadership and cash generation) are significant, but the company has signaled a pronounced near-term earnings challenge driven by pricing and policy — producing a balanced, watchful outlook.View all DE:NOVA earnings summariesNOVA Stock 12 Month Forecast
Average Price Target
€47.05
▲(15.19% Upside)
Technical Analysis
Options Prices
Currently, No data available
---